Cancer stem cellccRCCstem cell tumor-propagating cellThe present article highlights diverse roles of stem cells in healthy state, oncology and regenerative medicine in comparison to the Clear Cell Renal Cell Carcinoma (ccRCC) stem cells. Furthermore, we support the notion of urgent need to change ...
Renal cell carcinoma is the most common primary malignancy of the kidney. This tumor accounts for 2% of all cancer diagnoses in humans [1]. Among the RCC histologic subtypes, the vast majority are classified as clear cell renal cell carcinoma (CCRCC) [2]. Although renal tumors are usually ...
Clear cell renal cell carcinoma (ccRCC) is a complex disease with remarkable immune and metabolic heterogeneity. Here we perform genomic, transcriptomic, proteomic, metabolomic and spatial transcriptomic and metabolomic analyses on 100 patients with ccRCC from the Tongji Hospital RCC (TJ-RCC) cohort. ...
Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the tumor immune microenvironment of ccRCC, we applied single-cell-RNA sequencing (SCRS) along with T-c...
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer (Ricketts et al., 2018) with a rising global incidence (Smittenaar et al., 2016). Instances of spontaneous regression (Cole and Everson, 1956; Janiszewska et al., 2013; Snow and Schellhammer,...
The advent of PD1/PD-L1 inhibitors has significantly transformed the therapeutic landscape for clear cell renal cell carcinoma (ccRCC). This review provides an in-depth analysis of the biological functions and regulatory mechanisms of PD1 and PD-L1 in cc
Targeting apoptosis in clear cell renal cell carcinoma[J]. Biomed Pharmacother, 2024,175:116805. [2] Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases[J]. Cancer, 1971,28(5):1165-1177. [3] Pin...
More information:"Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: results from the phase III SWOG S0931 (EVEREST) trial." Poster presentation 1887P, Monday, October 23, 2023. ...
PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment wit...
In 2020, 431,288 people were newly diagnosed with kidney tumors and 179,368 patients with kidney tumors died worldwide1. Clear cell renal cell carcinoma (ccRCC) represents approximately 70% of kidney tumor cases in adults2. Analyses of The Cancer Genome Atlas (TCGA) and the Clinical Proteomics...